InterCure Ltd. (INCR) has demonstrated resilience in its first half of 2024 performance despite facing significant challenges, including disruptions at its southern Israeli facility. The company exceeded revenue estimates but continues to experience growth limitations due to the ongoing conflict. InterCure is investing heavily in restoring its facility and expects to return to full operational capacity in the coming quarters, aiming for double-digit sales growth in the second half of 2024.